This week, Frost & Sullivan—a global researching and consulting organization—together with Rani Therapeutics, a drug manufacturer developing an approach to the oral delivery of large-molecule drugs, announced the results of a combined research study. The study suggested that biosimilar developers could gain market share from brand-name biologics by developing the biosimilars in oral form.
This week, Frost & Sullivan—a global researching and consulting organization—together with Rani Therapeutics, a drug manufacturer developing an approach to the oral delivery of large-molecule drugs, announced the results of a combined research study. The study suggested that biosimilar developers could gain market share from brand-name biologics by developing the biosimilars in oral form.
The research included a survey of more than 500 patients, and more than 100 physicians, including rheumatologists and gastroenterologists. The survey found that 88% of patients and 86% of rheumatologists and gastroenterologists would likely switch from adalimumab (Humira) injections to once-daily pills if an effective oral alternative existed.
Additionally, the results of the study found that such an oral drug could increase patient compliance with treatment. This factor is especially notable in light of the survey’s finding that 62% of patients and 86% of physicians reported that patients either skip or consistently fail to inject the drug as prescribed.
“Humira is the number 1 selling drug in the world, yet this research shows that its sales and AbbVie’s revenues could potentially be threatened by oral adalimumab because of fear of needles and the associated lack of patient compliance. Combine those challenges with patent expiration and the increasing threat of biosimilars, which are forecast to hit the market in the coming years, and it’s the perfect storm,” said Mir Imran, chairman and CEO of Rani Therapeutics, in a statement.
However, the companies did not address the key question of whether regulatory bodies like the FDA or the European Medicines Agency would approve such an orally administered drug as a biosimilar of an injectable or infusible reference product, as such a drug would not be similar in its route of administration, and challenges with interchangeability (and therefore pharmacy-level substitution for the reference product) would be likely.
Rani Therapeutics is not the first drug maker to see the value in an orally delivered biologic, however. Just last month, Protalix BioTherapeutics, Inc, an Israel-based drug manufacturer, announced positive results from a phase 2 clinical trial for its own novel, orally administered anti-tumor necrosis factor (anti-TNF) drug, OPRX-106, for the treatment of inflammatory bowel disease.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.